Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae contributes more than 10,000 additional genetic variants to the ClinVar project

Invitae contributes more than 10,000 additional genetic variants to the ClinVar project

June 28, 2016

Contribution helps ensure genetic information is widely and freely available for peer-review in order to establish a new “gold standard” and to help clinical researchers improve healthcare 

Brings the company’s total contribution to more than 22,000 variants submitted 

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company has submitted information on more than 10,000 clinically observed genetic variants to the ClinVar project, an effort by the National Center for Biotechnology Information (NCBI) to aggregate ...

Read more


Genome Magazine Kicks Off “Code Talkers” National Essay Contest to Honor Genetic Counselors, Sponsored by Invitae

Genome Magazine Kicks Off “Code Talkers” National Essay Contest to Honor Genetic Counselors, Sponsored by Invitae

June 23, 2016

Clinicians, patients and families invited to submit essays recognizing the impact of genetic counselors

Finalists to be featured in a book and honored at National Society of Genetic Counselors (NSGC) Annual Education Conference

People across the U.S. are sharpening their pencils and honing their writing skills by taking part in Genome magazine’s Code Talker Award, an essay contest in which patients and their families pay tribute to a genetic counselor by nominating him or her for an award to ...

Read more


Invitae announces the launch of CancerCHECK to guide and support community oncologists through the hereditary cancer genetic testing process

Invitae announces the launch of CancerCHECK to guide and support community oncologists through the hereditary cancer genetic testing process

June 06, 2016

New tool launched at the 2016 ASCO Annual Meeting along with presentation of new data underscoring the importance of genetic testing in cancer care

To help community oncologists more easily follow clinical guidelines on the use of genetic testing, Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the availability of CancerCHECK (Cancer Complete Hereditary Evaluation Clinic Kit), a comprehensive support program. CancerCHECK provides checklists, information, and customized support free of charge for clinicians ...

Read more


Invitae now offers comprehensive, high-quality, affordable genetic testing in New York for hereditary cancer, cardiology, and epilepsy

Invitae now offers comprehensive, high-quality, affordable genetic testing in New York for hereditary cancer, cardiology, and epilepsy

May 31, 2016

Company received approval from New York State Department of Health

Expands customer base by over 19 million people

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company has completed the comprehensive Clinical Laboratory Evaluation Program and received its clinical laboratory permit from the state of New York. With this approval, Invitae now offers genetic testing in all 50 states, Canada, and other countries in the following test categories:

  • Hereditary cancer: Invitae has one of the most ...

Read more


Invitae to present at the UBS Global Healthcare Conference

Invitae to present at the UBS Global Healthcare Conference

May 11, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that members of the company’s management team will present at the UBS Global Healthcare Conference on Monday, May 23, 2016 at approximately 3:00 p.m. Eastern / 12:00 p.m. Pacific in New York City.

The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcast will be available shortly after the ...

Read more


Invitae announces first quarter 2016 financial results

Invitae announces first quarter 2016 financial results

May 09, 2016

Grew volume by more than 300% year over year, secured Medicare reimbursement and multiple private payer contracts, expanded test menu with more than 1,000 genes in production, lowered COGS

Hosting conference call at 4:45 pm ET / 1:45 pm PT

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced financial and operating results for the first quarter ended March 31, 2016. The company executed on all four of its key metrics, including important progress on reimbursement.

“We ...

Read more


Invitae to present at the Bank of America Merrill Lynch 2016 Health Care Conference

Invitae to present at the Bank of America Merrill Lynch 2016 Health Care Conference

April 28, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that members of the company’s management team will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 2016 at approximately 8:00 a.m. Pacific in Las Vegas.

The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcasts will be available shortly after the conclusion ...

Read more


Invitae to announce first quarter 2016 financial results and host conference call on May 9, 2016

Invitae to announce first quarter 2016 financial results and host conference call on May 9, 2016

April 25, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its first quarter 2016 financial results on Monday, May 9, 2016 and will host a conference call that day at 4:45 pm Eastern / 1:45 pm Pacific to discuss its financial results and recent developments.

 

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 92101487.

 

The ...

Read more


Invitae announces Medicare reimbursement for hereditary breast cancer-related disorders under a new CPT code for multi-gene panels

Invitae announces Medicare reimbursement for hereditary breast cancer-related disorders under a new CPT code for multi-gene panels

April 19, 2016

Medicare's MolDX policy expected to result in cost saving for hereditary cancer testing

Invitae Corporation (NYSE: NVTA), a genetic information company, announced that the Centers for Medicare and Medicaid Services (CMS) have begun providing payments for Invitae’s multi-gene tests for hereditary breast cancer-related disorders (e.g. hereditary breast cancer, hereditary ovarian cancer, and hereditary endometrial cancer). The tests are billed under the current procedure terminology (CPT) code 81432, which became effective on January 1, 2016. Payments are made by Noridian ...

Read more


Invitae presented data at the NCCN Annual Conference on the utility of multi-gene panels

Invitae presented data at the NCCN Annual Conference on the utility of multi-gene panels

April 01, 2016

Company offers multi-gene panels based on NCCN guidelines to help clinicians select tests for their individual patients

Invitae Corporation (NYSE: NVTA), a genetic information company, presented data on its guidelines-based genetic testing panels at the NCCN Annual Conference: Advancing the Standard of Cancer Care in Hollywood, Florida, on Thursday. Invitae offers guidelines-based panel testing that clinicians can customize to reflect their own diagnoses and expertise to ensure that clinicians have the right tests for the right patients.

"We have entered ...

Read more